Short answer
GLAUKOS Corp (GKOS) filed an 8-K current report with the SEC on July 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026, released July 29, 2026.
GLAUKOS Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026, released July 29, 2026
- Detailed financial results provided in Exhibit 99.1 press release
Item 7.01 · Regulation FD Disclosure
- Quarterly Summary covers Glaukos’ second quarter ended June 30, 2026
- Supplemental business and financial information available in Exhibit 99.2
- Investor relations website provides an additional access point for the quarterly materials
Item EX-99.1 · Exhibit EX-99.1
- Q2 net sales $185.6M, up 50% YoY, with glaucoma sales $155.2M and U.S. glaucoma sales $118.5M
- Gross margin improved to 81.7% from 78.3%; non-GAAP margin reached 84.5%
- GAAP operating loss narrowed to $17.3M from $22.7M; non-GAAP loss improved to $7.6M
- 2026 revenue guidance raised to $680M-$700M from $620M-$635M, signaling stronger expected demand
- $289.3M in cash, investments and restricted cash with no debt, supporting continued commercialization and pipeline investment
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other GLAUKOS Corp 8-K filings
Get the next GKOS 8-K as it lands
Follow GKOS for push alerts, or ask the research agent what this filing means.